Antithrombotic Strategies According to Age: Insights From the AUGUSTUS Trial.

Guimarães, Patricia O; Lopes, Renato D; Wojdyla, Daniel M; Alexander, John H; Goodman, Shaun G; Aronson, Ronald; Halvorsen, Sigrun; Sinnaeve, Peter; Vinereanu, Dragos; Storey, Robert F; Berwanger, Otavio; Windecker, Stephan; Mehran, Roxana; Granger, Christopher B; Alexander, Karen P (2024). Antithrombotic Strategies According to Age: Insights From the AUGUSTUS Trial. (In Press). The American journal of medicine Elsevier 10.1016/j.amjmed.2024.06.001

Text 1-s2.0-S0002934324003474-main.pdf - Accepted Version Restricted to registered users only until 12 June 2025. Available under License Publisher holds Copyright. Download (1MB) | Request a copy

OBJECTIVE

We aimed to evaluate the safety and efficacy of antithrombotic strategies by age in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention in AUGUSTUS.

METHODS

Patients were stratified into 3 age groups: <65, 65-74, and ≥75 years. Outcomes of interest were major or clinically relevant non-major bleeding, major bleeding, death or rehospitalization, and ischemic events. Treatment effects of apixaban vs. vitamin K antagonist (VKA) and aspirin vs. placebo were assessed across age groups using Cox models.

RESULTS

Of 4614 patients, 1267 (27.5%) were <65, 1802 (39.0%) were 65-74, and 1545 (33.5%) were ≥75 years. Apixaban was associated with lower rates of major or clinically relevant non-major bleeding than VKA (<65: HR 0.69 [0.47-1.00]; 65-74: HR 0.57 [0.43-0.75]; ≥75: HR 0.81 [0.63-1.04]). Death or hospitalization occurred less often with apixaban, regardless of age. No differences were observed in rates of ischemic events between apixaban and VKA according to age. Aspirin was associated with higher rates of bleeding than placebo (<65: HR 1.67 [1.15-2.43]; 65-74: HR 2.32 [1.73-3.10]; ≥75: HR 1.69 [1.31-2.19]). Rates of death or rehospitalization and ischemic events were similar among patients receiving aspirin or placebo across age groups.

CONCLUSIONS

Apixaban was associated with greater absolute reduction in bleeding than VKA in older age groups, reflecting their higher hemorrhagic risk. Aspirin increased bleeding in all age groups vs. placebo. Our findings support the use of apixaban plus a purinergic receptor P2Y12(P2Y12) inhibitor without aspirin in patients with atrial fibrillation and recent acute coronary syndrome/percutaneous coronary intervention, regardless of age.

Interest & Impact

Downloads

0 since deposited on 20 Jun 2024
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item